Page last updated: 2024-11-12

idopyranose

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

L-idose : The L-stereoisomer of idose. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

L-idopyranose : The pyranose form of L-idose. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID11030410
CHEBI ID86061
CHEBI ID37709
CHEBI ID86060
SCHEMBL ID3359776
MeSH IDM0056960

Synonyms (25)

Synonym
IDO ,
IDOSE ,
l-idose
A844159
(3r,4s,5s,6s)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol
idopyranose
SCHEMBL3359776
idopyranoside
l-ido
l-idopyranoside
l-idopyranose
l-(-)-idose
W-203218
C21050
(l)-idopyranose
mfcd00069825
(3r,4s,5s,6s)-6-(hydroxymethyl)tetrahydro-2h-pyran-2,3,4,5-tetraol
wurcs=2.0/1,1,0/[a2121h-1x_1-5]/1/
CHEBI:86061 ,
chebi:37709
chebi:86060
ido-hexose
l-ido-hexose
idose l-form
wurcs=2.0/1,1,0/(a2121h-1x_1-5)/1/
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
L-idoseThe L-stereoisomer of idose.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (31)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (6.45)18.7374
1990's0 (0.00)18.2507
2000's10 (32.26)29.6817
2010's14 (45.16)24.3611
2020's5 (16.13)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (3.13%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other31 (96.88%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]